摘要
目的研究瑞舒伐他汀对高血脂伴糖尿病患者血管内皮的保护作用。方法将76例高血脂伴糖尿病患者随机分为阿卡波糖组(n=38,口服阿卡波糖100 mg,3次/d)和瑞舒伐他汀组(n=38,在阿卡波糖组治疗基础上加服瑞舒伐他汀20 mg,1次/d),疗程4周。检测治疗前后2组患者体内血糖、血脂、内皮素(ET)、一氧化氮(NO)、C反应蛋白(CRT)和循环内皮细胞(CEC)水平。以38名健康者作为ET、NO、CRT和CEC检测的对照。结果阿卡波糖组治疗前后血脂、ET、NO、CRT和CEC水平差异无统计学意义(P>0.05)。与治疗前比较,瑞舒伐他汀组治疗后总胆固醇(TC)、低密度脂蛋白(LDL)、三酰甘油(TG)、ET、CRT和CEC水平显著降低(P<0.01),高密度脂蛋白(HDL)、NO水平显著升高(P<0.01),且与阿卡波糖组比较,差异有统计学意义(P<0.01)。结论瑞舒伐他汀可能通过调节血脂、NO、ET水平及其抗炎机制而发挥对血管内皮细胞的保护作用。
Objective To investigate the protective effects of rosuvastatin on vascular endothelial cells in hyperlipidemia patients with diabetes.Methods 76 hyperlipidemia patients with diabetes were randomly divided into acarbose group（n=38,took acarbose 100 mg orally thrice a day） and rosuvastatin group（n=38,took rosuvastatin 20 mg orally once a day on the basis of administration of acarbose group）.Both treatment course were 4 weeks.Levels of blood glucose,blood lipid,endothelin（ET）,nitric oxide（NO）,C-reactive protein（CRP） and circulating endothelial cells（CEC） of patients were measured in the two groups before and after treatment.38 healthy persons were selected as control for ET,NO,CRT and CEC detection.Results Levels of lood lipid,ET,NO,CRP and CEC of patients in acarbose group showed no significant difference between before and after treatment（P〉0.05）.Compared with treatment before,levels of total cholesterol（TC）,low density lipoprotein（LDL）,triacylglycerol（TG）,ET,CRP and CEC of patients in rosuvastatin group decreased obviously after treatment（P〈0.01）,while levels of high density lipoprotein（HDL） and NO increased markedly（P〈0.01）,and they demonstrated significant difference when compared with those in acarbose group（P〈0.01）.Conclusion Rosuvastatin plays a protective role on vascular endothelial cells probably through regulating blood lipid,NO,ET levels and its anti-inflammation mechanism.
出处
《重庆医学》
CAS
CSCD
北大核心
2011年第18期1815-1816,1819,共3页
Chongqing medicine
关键词
内皮细胞
C反应蛋白
糖尿病
高血脂
瑞舒伐他汀
endothelial cells
C-reactive protein
diabetes mellitus
hyperlipidemia
rosuvastatin
